Effect of edaravone on the matrix metal-oproteinase-9 (MMP-9) expression after thrombolytic therapy for cerebral ischemia in rats

孙立军,刘晨,李智文,卢金华
DOI: https://doi.org/10.3969/j.issn.1673-5110.2011.23.002
2011-01-01
Abstract:Objective To explore the neuroprotective mechanism of edaravone after thrombolytic therapy by studying the effect of edaravone on the matrix metal-oproteinase-9(MMP-9) expression,blood-brain barrier(BBB) following thrombolytic therapy in urokinase after focal cerebral ischemia in rats.Methods The middle cerebral artery(MCA) of Sprague-Dawley rat was occluded by autologous blood clots.Rats were randomly assigned to sham-operated group(sham group),urokinase therapy group(UK group) and urokinase with edaravone group(UK+ED group).The expression of matrix MMP-9 in brain tissue was observed by immunohistochemistry.The permeability of blood-brain barrier was evaluated based on leakage of Evans blue and the content of EB in the brain tissue was measured by spectrophotometry.Results Contrast to UK group,the combination of UK and ED significantly decreased MMP-9 expression in the side of ischemia brain(P<0.01).Contrast to UK group,the combination of UK and ED significantly reduced EB content in the side of ischemia brain(P<0.01).Conclusion It is assumed that edaravone may inhibit MMP-9 expression,then relieve the damage of reperfusion to BBB,and may prolong the thrombolytic therapeutic time window.
What problem does this paper attempt to address?